Real-World Effectiveness of J&J Vaccine

Researchers from the USA and India have conducted a study to determine a study demonstrating the real-world effectiveness of a single dose of J&J Ad26.COV2.S vaccine at preventing COVID-19. The study published on a pre-print server compared the SARS-CoV-2 infection rate was compared between 2,195 individuals who received a single dose of the Ad26.COV2.S vaccine and 21,950 unvaccinated, propensity-matched individuals. The team reports that thirteen (0.59%) of 2,195 vaccines tested positive for SARS-CoV-2 by polymerase chain reaction (PCR), compared with 262 (1.19%) of 21,950 unvaccinated individuals.

The incidence rate of SARS-CoV-2-positive tests in the vaccinated and unvaccinated cohorts was 0.18 and 0.36 cases per 1000 person-days, respectively, indicating an overall vaccine efficacy of 50.6%. However, “the full effectiveness of Ad26.COV2.S is expected to be achieved after several weeks,” explains the team. Of 1,779 vaccinated individuals with at least two weeks of follow-up data available, only 3 (0.17%) tested positive for SARS-CoV-2 from day 15 or more following vaccination, compared with 128 (0.72%) of 17,744 unvaccinated individuals.

This corresponds to the efficacy of 76.7% in preventing SARS-CoV-2 infection with symptom onset at least two weeks following vaccination, says the team. The researchers say the study data are consistent with the 66.9% efficacy (66.9%) in preventing moderate-to-severe COVID-19 reported in the phase 3 trial.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link: https://www.medrxiv.org/content/10.1101/2021.04.27.21256193v1

#Featured